- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Urothelial carcinoma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 436KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 70KB)
Avelumab – March 2022
Avelumab: Solution concentrate for I.V. infusion 200 mg in 10 mL; Bavencio®
Last updated
7 July 2022